These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 16203772)

  • 1. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome.
    Sotamaa K; Liyanarachchi S; Mecklin JP; Järvinen H; Aaltonen LA; Peltomäki P; de la Chapelle A
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6840-4. PubMed ID: 16203772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
    Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
    Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
    Menin C; Scaini MC; De Salvo GL; Biscuola M; Quaggio M; Esposito G; Belluco C; Montagna M; Agata S; D'Andrea E; Nitti D; Amadori A; Bertorelle R
    J Natl Cancer Inst; 2006 Feb; 98(4):285-8. PubMed ID: 16478747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
    Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
    J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
    Bougeard G; Baert-Desurmont S; Tournier I; Vasseur S; Martin C; Brugieres L; Chompret A; Bressac-de Paillerets B; Stoppa-Lyonnet D; Bonaiti-Pellie C; Frebourg T
    J Med Genet; 2006 Jun; 43(6):531-3. PubMed ID: 16258005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC).
    Krüger S; Bier A; Engel C; Mangold E; Pagenstecher C; von Knebel Doeberitz M; Holinski-Feder E; Moeslein G; Schulmann K; Plaschke J; Rüschoff J; Schackert HK;
    J Med Genet; 2005 Oct; 42(10):769-73. PubMed ID: 16199549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
    Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
    Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
    Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
    DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
    Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
    Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland.
    Campbell PT; Edwards L; McLaughlin JR; Green J; Younghusband HB; Woods MO
    Clin Cancer Res; 2007 Jul; 13(13):3783-8. PubMed ID: 17606708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
    Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
    BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
    Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
    Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
    J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells.
    Alazzouzi H; Suriano G; Guerra A; Plaja A; Espín E; Armengol M; Alhopuro P; Velho S; Shinomura Y; González-Aguilera JJ; Yamamoto H; Aaltonen LA; Moreno V; Capellà G; Peinado MA; Seruca R; Arango D; Schwartz S
    J Med Genet; 2007 Jan; 44(1):75-80. PubMed ID: 16825434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
    Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
    Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
    Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
    Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.